Citation Impact
Citing Papers
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
2015 Standout
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
2019
ADAPT: An Algorithm Incorporating PRO‐C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis
2018
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
2017
Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis
2020
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study
2021
Hepatitis C Virus in Vietnam: High Prevalence of Infection in Dialysis and Multi-Transfused Patients Involving Diverse and Novel Virus Variants
2012
A positive feedback loop between RIP 3 and JNK controls non‐alcoholic steatohepatitis
2014
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe
2019
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
2018
Non-alcoholic fatty liver disease
2017
Cancer Statistics, 2021
2021 Standout
Chapter 3 Carnosine and Its Possible Roles in Nutrition and Health
2009
Confounding factors of non-invasive tests for nonalcoholic fatty liver disease
2020
Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications
2017
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity
2017
Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study
2016
Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease
2019
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
2022
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
2018
Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices
2020
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
2012
Autoimmune hepatitis
2018
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease
2016
Nonalcoholic fatty liver disease and aging: Epidemiology to management
2014
Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
2016
On the enigma of carnosine’s anti-ageing actions
2008
Non-alcoholic fatty liver disease – A global public health perspective
2018 Standout
Necroptosis and its role in inflammation
2015 StandoutNature
New trends on obesity and NAFLD in Asia
2017
Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis
2017
Hepatocellular carcinoma
2018 Standout
Obesity, inflammation, and liver cancer
2011
NAFLD: Reporting Histologic Findings in Clinical Practice
2020
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
2020
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD )
2022
NAFLD prevalence differs among hispanic subgroups: The multi-ethnic study of atherosclerosis
2014
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Burden of liver diseases in the world
2018 Standout
Mortality From Chronic Liver Diseases in Diabetes
2014
Liver cirrhosis
2014
Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease
2013
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
2013 StandoutNature
Functions of autophagy in normal and diseased liver
2013
Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi-supercentenarians
2015
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms
2015
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
2019
Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease
2011
Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-Up
2013
The changing epidemiology of liver diseases in the Asia–Pacific region
2018
Nonalcoholic Fatty Liver Disease Epidemic and Its Implications for Liver Transplantation
2013
Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
2017
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
2022
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
2017
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
2020
A position statement on NAFLD/NASH based on the EASL 2009 special conference
2010
Alterations in Ventricular Structure and Function in Obese Adolescents with Nonalcoholic Fatty Liver Disease
2012
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
2016
Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis
2015
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
2014 Standout
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients
2012
Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World
2015
Nonalcoholic fatty liver disease in Asia: emerging perspectives
2016
Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease
2018
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011–2012
2014
Mechanisms and disease consequences of nonalcoholic fatty liver disease
2021
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
2012
Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis
2020
Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality
2016
NAFLD and diabetes mellitus
2016
The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma
2016
Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis
2015
Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease
2014
Treatment of NAFLD with diet, physical activity and exercise
2017
Gaps in Recognition and Evaluation of Incidentally Identified Hepatic Steatosis
2014
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
2017
Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic Steatohepatitis
2009
From NAFLD in clinical practice to answers from guidelines
2013
Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases
2016
Pharmacological agents for NASH
2013
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease
2014
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Nonobese Fatty Liver Disease
2016
Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
2016
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
2020
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
2020
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
2018
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
2015 Standout
Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions
2018
Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile
2014
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
2020
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
2017
Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies
2020
Non-alcoholic fatty liver disease
2021 Standout
Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: Results from the ATTICA prospective cohort study
2020
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography
2011
Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults
2011 Standout
Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
2017
Gender and racial differences in nonalcoholic fatty liver disease
2014
Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population
2014
Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity
2010
Relation of Physical Activity to Prevalence of Nonalcoholic Fatty Liver Disease Independent of Cardiometabolic Risk
2014
Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial
2014
Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999–2016
2021
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource
2013 StandoutNobel
The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis
2015
Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications
2011
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
2013
Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes
2015
Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
2018
Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity
2010
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
2013
Epidemiology and natural history of non-alcoholic fatty liver disease
2016
Insulin resistance, inflammation, and non-alcoholic fatty liver disease
2008
Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis
2019
Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations
2016
Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry
2018
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
Global burden of liver disease: 2023 update
2023 Standout
Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis
2021
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
2016
Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis
2021
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
2019
Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids
2018 StandoutNobel
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
2017
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
2010 Standout
Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography
2015
Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States
2022
Orlistat for overweight subjects with nonalcoholic steatohepatitis
2008
Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis
2015
Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice
2013
Underestimation of Liver-Related Mortality in the United States
2013
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
2012
Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019
2021
Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease
2011
NAFLD in Asia—as common and important as in the West
2013
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
2019
Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016
2018
Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis
2018
Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL)
2016
Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants
2011
Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies
2018
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
2020
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Prognostic Value of Controlled Attenuation Parameter by Transient Elastography
2017
Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis
2008
Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients
2016
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
2014
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis
2016
Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials
2022
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Sustained telomere length in hepatocytes and cholangiocytes with increasing age in normal liver
2012
In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not
2012
The Natural History of Nonalcoholic Fatty Liver Disease—An Evolving View
2017
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data
2017
Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease
2015
Extrahepatic complications of nonalcoholic fatty liver disease
2013
The cytotoxic mechanism of malondialdehyde and protective effect of carnosine via protein cross-linking/mitochondrial dysfunction/reactive oxygen species/MAPK pathway in neurons
2010
Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies
2015
Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C
2014
Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications
2016
Past, present and future perspectives in nonalcoholic fatty liver disease
2019
Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients
2020
Nonalcoholic Fatty Liver Disease as a Contributor to Hypercoagulation and Thrombophilia in the Metabolic Syndrome
2009
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
2016
Carnosine: New concept for the function of an old molecule
2012
Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis
2018
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
2014
NAFLD: A multisystem disease
2015 Standout
Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease
2016
Adipokines in liver diseases #
2009
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
2018 Standout
A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis
2018
Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis
2018
Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease
2017
Hepatocellular carcinoma
2022 Standout
Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis
2017
An apoptosis panel for nonalcoholic steatohepatitis diagnosis
2010
AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review
2020
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
2020
Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
2018
Ethnic and Gender Differences in the Prevalence of Nonalcoholic Steatohepatitis Among Bariatric Surgery Patients
2016
Physiology and Pathophysiology of Carnosine
2013 Standout
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
NASH in Lean Individuals
2019
A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis
2020 StandoutNobel
Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
2021
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
2013
Hepatocellular Carcinoma
2019 Standout
Nonalcoholic fatty liver disease‐related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma
2017
Trial design in NASH—realities and challenges
2011
The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017
2020
Patterns and predictors of mortality and disease progression among patients with non‐alcoholic fatty liver disease
2020
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
2018 Standout
Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta‐Analysis
2020
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
2021
Systematic review with meta‐analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease
2017
Development of a Novel Clinical Staging Model for Cirrhosis Using the Nationwide Inpatient Sample
2018
Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease
2014
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
2016
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
2019
Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
2015
Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey
2014
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
2019
Impact of coffee on liver diseases: a systematic review
2013
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
2016
Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study
2020
Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries.
2017
Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis
2020
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
2017 Standout
A randomized controlled trial on the effectiveness of 8-week high-intensity interval exercise on intrahepatic triglycerides, visceral lipids, and health-related quality of life in diabetic obese patients with nonalcoholic fatty liver disease
2019
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis
2021
Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States
2018
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
2017
Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real‐World Data From a Large U.S. Claims Database
2018
Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
2015
The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes
2016
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Patient‐Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition
2018
Is there an ‘ideal’ diet for patients with NAFLD?
2021
Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990–2017: a population-based observational study
2020
Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection—Liver: The “Musketeer” in the Spotlight
2016
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
2021
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
2015
2022
Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
2018
Survey of health status, nutrition and geography of food selection of chronic liver disease patients
2014
Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease
2019
Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
2016
Dose–response relationships of accelerometer‐measured sedentary behaviour and physical activity with non‐alcoholic fatty liver disease
2021
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
2014 Standout
Screening for Hepatitis C Virus Infection in Adolescents and Adults
2020
Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment
2017
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
2019
Review article: emerging anti‐fibrotic therapies in the treatment of non‐alcoholic steatohepatitis
2016
The independent predictors of non‐alcoholic steatohepatitis and its individual histological features.
2016
Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study
2015
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
2023 Standout
Burden of Disease Associated with Dietary Exposure to Aflatoxins in China in 2020
2022
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
2020
The Science of Obesity Management: An Endocrine Society Scientific Statement
2018
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
2020
Serum cytokeratin‐18 in the diagnosis of non‐alcoholic steatohepatitis: A meta‐analysis
2013
Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients
2019
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD
2020
Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research
2012
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
2021
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis
2016
Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis
2016
Updated thresholds for serum alanine aminotransferase level in a large‐scale population study composed of 34 346 subjects
2012
Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
2015
Coronary artery disease in decompensated patients undergoing liver transplantation evaluation
2018
The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population
2016
NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management
2019
Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: A prospective cohort study
2015
Magnetic resonance elastography plus Fibrosis‐4 versus FibroScan–aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH‐related fibrosis
2021
Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999–2016
2020
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
2020
Trends in Liver Disease Etiology Among Adults Awaiting Liver Transplantation in the United States, 2014-2019
2020
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
2017 Standout
The prevalence of nonalcoholic fatty liver disease in the Americas
2014
Readiness for behaviour change in non‐alcoholic fatty liver disease: implications for multidisciplinary care models
2014
Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States
2019
NAFLD and Chronic Kidney Disease
2016
Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies
2015
Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study
2014
Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease
2013
Objectively Measured Physical Activity Is Inversely Associated With Nonalcoholic Fatty Liver Disease: The Rotterdam Study
2021
Hepatic steatosis in diabetic patients does not predict adverse liver‐related or cardiovascular outcomes
2013
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
2017
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease
2018
Nonalcoholic Fatty Liver Disease
2015 Standout
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation
2017
High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes
2020
Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis
2019
Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop
2014
Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
2021
Liver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening
2018
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
2021
Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD
2021
Systematic review with meta‐analysis: risk of hepatocellular carcinoma in non‐alcoholic steatohepatitis without cirrhosis compared to other liver diseases
2018
From NAFLD to MAFLD: Implications of a Premature Change in Terminology
2020
Works of Maria Stepanova being referenced
The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon‐ and ribavirin‐free regimens: a study of health‐related quality of life
2015
Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study
2014
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
2016
Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis
2019
Associations of chronic hepatitis C with metabolic and cardiac outcomes
2013
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
2020
Gene expression profile associated with superimposed non‐alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C
2009
Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C
2016
Anthropometric and Clinical Factors Associated with Mortality in Subjects with Nonalcoholic Fatty Liver Disease
2012
Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality From Liver Cancer in the United States
2010
Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument
2017
Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C)
2013
Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States
2012
Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study
2010
A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis
2010
Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS)
2010
Superiority of Interferon-Free Regimens for Chronic Hepatitis C
2017
Hepatic Gene Expression of Caucasian and African-American Patients with Obesity-Related Non-Alcoholic Fatty Liver Disease
2010
Predictors of health‐related quality of life in patients with chronic liver disease
2009
A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH)
2008
Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
2013
Trends in Outpatient Resource Utilizations and Outcomes for Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease
2014
In-Hospital Mortality and Economic Burden Associated With Hepatic Encephalopathy in the United States From 2005 to 2009
2012
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir
2015
Clinical predictors of fibrosis in patients with chronic liver disease
2010
Vietnamese community screening for hepatitis B virus and hepatitis C virus
2010
Direct and Indirect Economic Burden of Chronic Liver Disease in the United States
2016
Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C
2013
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options
2018
Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis
2018
Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality
2011
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin
2015
Independent Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in the US Population
2012
Adipokines and cytokines in non‐alcoholic fatty liver disease
2007
Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008
2011
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
2020
Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis
2019
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis
2019
Depression in Patients with Nonalcoholic Fatty Liver Disease and Chronic Viral Hepatitis B and C
2011
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
2018
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis
2016
Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
2009
Caffeine is protective in patients with non‐alcoholic fatty liver disease
2011
Carnisone Increases Efficiency of DOPA Therapy of Parkinson's Disease: A Pilot Study
2008
A disease‐specific quality of life instrument for non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis: CLDQ ‐NAFLD
2017
Age-independent rise of inflammatory scores may contribute to accelerated aging in multi-morbidity
2015
Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib
2018
Epidemiology of chronic liver diseases in the USA in the past three decades
2019
Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C
2013
Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States
2017
Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes
2020
1334 CLINICAL AND ANTHROPOMETRIC FACTORS ASSOCIATED WITH LIVER-SPECIFIC MORTALITY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
2012
Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians
2020
Statin use is not associated with liver related mortality
2014
Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease
2016
Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: Data from Hong Kong
2020
Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life
2019
Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease
2017
Health‐related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir
2017
Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin
2017
1333 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH LOW LEVEL OF PHYSICAL ACTIVITY: A POPULATION-BASED STUDY
2012
Non‐alcoholic fatty liver disease (NAFLD ) is associated with low level of physical activity: a population‐based study
2012
Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
2018
Non-alcoholic steatofibrosis is independently associated with both overall mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)
2017
Anti‐adipocyte antibody response in patients with non‐alcoholic fatty liver disease
2014
Improvement of hepatic fibrosis in patients with non-alcoholic steatohepatitis treated with selonsertib is associated with improvement of patient-reported outcomes (PROS)
2017